From: MedPage Today [mailto:[log in to unmask]] 
Sent: December 07, 2011 14:32
To: [log in to unmask]
Subject: Breaking News: Pradaxa Benefit Outweighs Bleeding Risk, FDA Says



Wednesday December 07, 2011
Pradaxa Benefit Outweighs Bleeding Risk, FDA Says 
The FDA has announced that patients taking the anticoagulant dabigatran (Pradaxa) to reduce the risk of stroke associated with atrial fibrillation should continue to take the drug as directed, despite post-market reports of severe bleeding.
http://www.medpagetoday.com/Cardiology/Arrhythmias/30075?utm_source=breaking-news&utm_medium=email&utm_campaign=breaking-news

You have received this email because you have registered to receive alert emails at
www.medpagetoday.com, with the email address: [log in to unmask]

Change ALL email settings

Instant Unsubscribe from "Breaking News Alerts"

TECHNICAL QUESTIONS:
[log in to unmask]
MedPage Today, LLC. - Overlook at Great Notch - 150 Clove Road - Little Falls, New Jersey 07424 - Tel: (973) 890-0985 - Fax: (973) 890-1327 

-----------------------

To change your mail settings or leave the C-PALSY list, go here:

http://listserv.icors.org/SCRIPTS/WA-ICORS.EXE?SUBED1=c-palsy